Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty

Ludia Chiarugi, Domenico Prisco, Emilia Antonucci, Monia Capanni, Sandra Fedi, Agatina Alessandrello Liotta, Massimo Margheri, Ignazio Simonetti, Gian Franco Gensini, Rosanna Abbate

Research output: Contribution to journalArticlepeer-review

Abstract

Recent reports have shown the importance of new risk factors for cardiovascular disease. We investigated the relationship between Lp(a), fibrinolytic parameters and anticardiolipin antibodies (aCL) and the occurrence of clinical recurrence owing to restenosis after elective balloon percutaneous transluminal coronary angioplasty (PTCA) without stenting. In 167 patients, undergoing PTCA, Lp(a) plasma levels, aCL, euglobulin lysis time (ELT), plasminogen activator inhibitor-1 (PAI-1) activity and tissue-type plasminogen activator (t-PA) plasma levels were evaluated before the procedure. During follow-up 29 patients underwent clinical recurrence due to restenosis. Lp(a) levels were significantly higher in patients with restenosis in comparison to those without (P450 mg/L. Kaplan-Meier survival estimate showed an earlier occurrence of restenosis in patients with base-line Lp(a)>300 mg/l associated with aCL positivity. High Lp(a) plasma levels play a role in the occurrence of clinical recurrence due to restenosis after elective balloon PTCA without stenting; the association with aCL accelerates the development of restenosis.

Original languageEnglish
Pages (from-to)129-135
Number of pages7
JournalAtherosclerosis
Volume154
Issue number1
DOIs
Publication statusPublished - 2001

Keywords

  • Anticardiolipin antibodies
  • Fibrinolysis
  • Lp(a)
  • PTCA
  • Restenosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Lipoprotein (a) and anticardiolipin antibodies are risk factors for clinically relevant restenosis after elective balloon percutaneous transluminal coronary angioplasty'. Together they form a unique fingerprint.

Cite this